




Supplementary Figure 1 | FLT3 surface expression on CD34⁺ HSPCs from healthy donors and AML blasts. (A, B) Surface FLT3 expression of CD34⁺ healthy donor (HD) HSPCs was assessed by flow cytometry. (C, D) Surface FLT3 expression of CD34⁺CD38⁻ (C) and CD34⁺CD38⁺ (D) HD HSPCs, assessed by flow cytometry. (E, F) Surface FLT3 expression on *de novo* AML blasts (E) and its comparison with normal CD34⁺ HSPCs from the same AML patient (F). AML, acute myeloid leukemia; HSPC, hematopoietic stem and progenitor cells. Cell counts are normalized across different mean fluorescence intensity (MFI) values. Representative data from one of seven healthy donors and one of four AML patients are shown.